Ahlcon Parenterals (india) Limited

Ahlcon Parenterals (India) Limited, established on January 20, 1992, is a prominent Indian pharmaceutical company specializing in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is headquartered in New Delhi, India, with its registered office located at Plot No. 30 & 30/E, 2nd Floor, Shivaji Marg, Najafgarh Road Industrial Area, New Delhi, Delhi 110015.

In 2012, Ahlcon Parenterals was acquired by B. Braun Medical (India) Pvt. Ltd., a subsidiary of the German multinational B. Braun Melsungen AG. This acquisition has enhanced the company's quality practices and expanded its business channels. The company is classified as a public limited company under the Corporate Identification Number (CIN) U24239DL1992PLC047245.

As of the latest available data, Ahlcon Parenterals has an authorized share capital of ₹180,000,000 and a paid-up capital of ₹72,001,500. The company employs a dedicated workforce committed to delivering high-quality pharmaceutical products. For more information, visit their official website at www.ahlconindia.com.

Ahlcon Parenterals operates state-of-the-art manufacturing facilities located in Bhiwadi, Rajasthan. These facilities are equipped with advanced technology, including aseptic Blow-Fill-Seal (BFS) technology imported from Europe and the U.S., ensuring the production of Large Volume Parenterals (LVP) and Small Volume Parenterals (SVP) in a sterile environment. The company's manufacturing capacity has been expanded over the years to meet both domestic and international demand. Specific capacity details are not publicly disclosed.

The leadership team at Ahlcon Parenterals comprises experienced professionals dedicated to steering the company towards growth and excellence. The Managing Director is Indranil Mukherjee, who has been with the company since August 18, 2017. The Chairman is Andreas Walde, serving as a Non-Executive Director since March 18, 2016. Other key executives include Arun Kumar Gupta, Shiv Charan Lal Gupta, Suninder Singh Arora, Christoph Mueller, and Gabriel Sabate Parayre, who hold various directorial positions within the company.

Ahlcon Parenterals has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company adheres to stringent regulatory standards, ensuring compliance with Good Manufacturing Practices (GMP) and obtaining necessary approvals for its products. While specific regulatory filings and approvals are not publicly disclosed, the company's commitment to quality is evident through its ISO certifications, including ISO 9001:2015 for Quality Management Systems, ISO 14001 for Environmental Management Systems, and ISO 45001 for Occupational Health and Safety Management Systems.

Ahlcon Parenterals has expanded its footprint into emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to international quality standards, including ISO certifications, facilitates its entry into these markets. Additionally, the company's association with the B. Braun Group enhances its credibility and acceptance in these regions.

Ahlcon Parenterals demonstrates a strategic approach to geographic diversification, balancing its presence in both regulated and emerging markets. This strategy mitigates concentration risk and positions the company for sustainable growth. The acquisition by B. Braun Medical (India) Pvt. Ltd. in 2012 has further strengthened its global reach and operational capabilities.

Specific details regarding Ahlcon Parenterals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's adherence to international quality standards, including ISO certifications, indicates a commitment to meeting regulatory requirements in the U.S. market.

Ahlcon Parenterals' manufacturing facilities comply with Good Manufacturing Practices (GMP) standards, as evidenced by its ISO certifications. While specific WHO prequalification and EU GMP certificates are not publicly disclosed, the company's commitment to quality and sustainability aligns with international standards.

Ahlcon Parenterals holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and relevant state drug controllers, ensuring compliance with Indian regulatory requirements. The company's adherence to ISO standards further demonstrates its commitment to quality and regulatory compliance.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Ahlcon Parenterals. The company's commitment to quality is underscored by its ISO certifications, including ISO 9001:2015, ISO 14001, and ISO 45001.

Ahlcon Parenterals operates in a competitive landscape, facing competition from both domestic and international pharmaceutical companies. While specific market share data is not publicly available, the company's focus on quality, adherence to international standards, and strategic partnerships, such as its association with the B. Braun Group, position it favorably in the market.

Ahlcon Parenterals' key differentiators include its commitment to a Zero Defect Quality policy, utilization of advanced manufacturing technologies like aseptic Blow-Fill-Seal (BFS) technology, and adherence to international quality standards through ISO certifications. The acquisition by B. Braun Medical (India) Pvt. Ltd. has further enhanced its operational capabilities and market reach.

Ahlcon Parenterals maintains a strategic focus on manufacturing finished pharmaceutical formulations, including Large Volume Parenterals (LVP) and Small Volume Parenterals (SVP). The company's future outlook includes expanding its presence in both regulated and emerging markets, leveraging its quality manufacturing capabilities and strategic partnerships to drive growth.

Ahlcon Parenterals has a strong track record in manufacturing high-quality pharmaceutical formulations, as evidenced by its ISO certifications and adherence to international quality standards. The company's export volume and consistency are supported by its strategic partnerships, including its association with the B. Braun Group. Reliability indicators include its commitment to a Zero Defect Quality policy and utilization of advanced manufacturing technologies.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: Confirm the company's FDA facility registration status through the FDA's official website.

• WHO-GMP Certification: Verify WHO Good Manufacturing Practices certification through the World Health Organization's official website.

• EU GMP Certification: Check for EU Good Manufacturing Practices certification through the European Medicines Agency's official website.

• ISO Certifications: Review ISO 9001:2015, ISO 14001, and ISO 45001 certifications, which can be obtained from the company's official website or directly from the International Organization for Standardization.

Importers should undertake the following steps to ensure due diligence:

• Verify Regulatory Approvals: Confirm FDA registration, WHO-GMP, and EU GMP certifications through the respective official websites.

• Assess Quality Certifications: Review ISO certifications to ensure adherence to international quality standards.

• Evaluate Financial Stability: Review the company's financial statements and annual reports to assess financial health.

• Inspect Manufacturing Facilities: If possible, conduct site visits to evaluate manufacturing practices and compliance with quality standards.

• Review Product Portfolio: Analyze the product range to ensure alignment with market needs and regulatory requirements.

• Check for Regulatory Actions: Investigate any past regulatory actions, such as warning letters or import alerts, to assess